CFDE Data Portal | Search LOC124903670

	Label	Description
	LOC124903670 Gene (Entity type)	ENSG00000246465 - uncharacterized LOC124903670
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 11 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE190937 AHCY MAT2A knockout Rael 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE222758 clofazimine U2OS 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE142357 HDAC3 inhibition 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC124903670

ENSG00000246465 - uncharacterized LOC124903670

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 7 human up

A Gene Set from LINCS

GSE108464 AZ-628 11 v 12 human up

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 3 human dn

A Gene Set from LINCS

GSE190937 AHCY MAT2A knockout Rael 4 v 3 human dn

A Gene Set from LINCS

GSE222758 clofazimine U2OS 0 v 2 human dn

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 7 human dn

A Gene Set from LINCS

GSE142357 HDAC3 inhibition 1 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.